Cabaletta Bio, a clinical-stage biotechnology company focused on engineered T cell therapies for B-cell mediated autoimmune diseases, further expanded its ongoing sponsored research agreement with Penn this year to include three additional B cell-mediated autoimmune disease targets.
The research is being conducted under the direction of Aimee Payne, PhD, associate professor of dermatology in Penn’s Perelman School of Medicine and director of the Penn Autoimmunity Center of Excellence, who co-founded the company along with Michael Milone, Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania.
